Fig. 4: Performance metrics of the ctDNA assay and association between early ctDNA dynamics and. residual cancer burden (RCB) class.
From: Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors
A The positive predictive value (PPV) and sensitivity for predicting moderate or extensive RCB (RCB-II/III), the negative predictive value (NPV) and specificity for predicting pathologic complete response or limited RCB (RCB-0/I) were calculated in patients across receptor subtypes: hormone receptor (HR)-positive/HER2-negative (HR + HER2-, left panel), triple-negative breast cancer (TNBC, middle panel), or HER2-positive (HER2 + , right panel). ctDNA testing was performed at pretreatment (T0), weeks 3 (T1) and 12 (T2) after treatment initiation, and post-NAT before surgery (T3). B Pie charts showing the proportion of patients by early ctDNA dynamics groups by subtype. C Bar plots showing the proportion of RCB classes in each early ctDNA dynamics group. The percentages may not add up to 100% due to rounding. The p-values were calculated using the Chi-squared test. D Forest plots from logistic regression analyses showing odds ratio estimates and 95% confidence intervals. The p-values were calculated from likelihood ratio tests.
